Literature DB >> 21982832

Stachybotrys chartarum-induced hypersensitivity pneumonitis is TLR9 dependent.

Urvashi Bhan1, Michael J Newstead, Xianying Zeng, Megan N Ballinger, Louis R Standiford, Theodore J Standiford.   

Abstract

Hypersensitivity pneumonitis (HP), an inflammatory lung disease, develops after repeated exposure to inhaled particulate antigen and is characterized by a vigorous T helper type 1-mediated immune response, resulting in the release of IL-12 and interferon (IFN)-γ. These T helper type 1 cytokines may participate in the pathogenesis of HP. Stachybotrys chartarum (SC) is a dimorphic fungus implicated in a number of respiratory illnesses, including HP. Here, we have developed a murine model of SC-induced HP that reproduces pathology observed in human HP and hypothesized that toll receptor-like 9 (TLR9)-mediated dendritic cell responses are required for the generation of granulomatous inflammation induced by inhaled SC. Mice sensitized and challenged with 10(6) SC spores develop granulomatous inflammation with multinucleate giant cells, accompanied by increased accumulation of neutrophils and CD4(+) and CD8(+) T cells. SC sensitization and challenge resulted in robust pulmonary expression of tumor necrosis factor-α, IL-12, and IFN-γ. SC-mediated granulomatous inflammation required IFN-γ and was TLR9 dependent, because TLR9(-/-) mice displayed reduced peribronchial inflammation, decreased accumulation and/or activation of polymorphonuclear (PMN) and CD4(+) and CD8(+) T cells, and reduced lung expression of type 1 cytokines and chemokines. T-cell production of IFN-γ was IL-12 dependent. Our studies suggest that TLR9 is critical for dendritic cell-mediated development of a type 1 granulomatous inflammation in the lung in response to SC.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982832      PMCID: PMC3260863          DOI: 10.1016/j.ajpath.2011.08.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

Review 1.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

2.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.

Authors:  A Ozinsky; D M Underhill; J D Fontenot; A M Hajjar; K D Smith; C B Wilson; L Schroeder; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  Recognition of pathogen-associated molecular patterns by TLR family.

Authors:  Shizuo Akira; Hiroaki Hemmi
Journal:  Immunol Lett       Date:  2003-01-22       Impact factor: 3.685

Review 4.  Hypersensitivity pneumonitis.

Authors:  Eunhee S Yi
Journal:  Crit Rev Clin Lab Sci       Date:  2002-11       Impact factor: 6.250

5.  Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide.

Authors:  Jian Jun Gao; Veronica Diesl; Tatiana Wittmann; David C Morrison; John L Ryan; Stefanie N Vogel; Maximillian T Follettie
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

Review 6.  Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis.

Authors:  M Suga; H Yamasaki; K Nakagawa; H Kohrogi; M Ando
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1997-09       Impact factor: 0.670

7.  Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis.

Authors:  E Israël-Assayag; M Fournier; Y Cormier
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

8.  Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells.

Authors:  Huazhang An; Yizhi Yu; Minghui Zhang; Hongmei Xu; Runzi Qi; Xiaoyi Yan; Shuxun Liu; Wenya Wang; Zhenghong Guo; Jun Guo; Zhihai Qin; Xuetao Cao
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

Review 9.  Pathogenesis of hypersensitivity pneumonitis.

Authors:  Melissa Girard; Evelyne Israël-Assayag; Yvon Cormier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2004-04

Review 10.  Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells.

Authors:  Linda A Lieberman; Christopher A Hunter
Journal:  Microbes Infect       Date:  2002-12       Impact factor: 2.700

View more
  5 in total

1.  A critical role of Dectin-1 in hypersensitivity pneumonitis.

Authors:  Mari Higashino-Kameda; Toshiki Yabe-Wada; Shintaro Matsuba; Kazuya Takeda; Kazushi Anzawa; Takashi Mochizuki; Koichi Makimura; Shinobu Saijo; Yoichiro Iwakura; Hirohisa Toga; Akira Nakamura
Journal:  Inflamm Res       Date:  2015-12-07       Impact factor: 4.575

2.  TLR9-dependent IL-23/IL-17 is required for the generation of Stachybotrys chartarum-induced hypersensitivity pneumonitis.

Authors:  Urvashi Bhan; Michael J Newstead; Xianying Zeng; Amy Podsaid; Moloy Goswami; Megan N Ballinger; Steven L Kunkel; Theodore J Standiford
Journal:  J Immunol       Date:  2012-11-23       Impact factor: 5.422

3.  Hypersensitivity pneumonitis onset and severity is regulated by CD103 dendritic cell expression.

Authors:  Emilie Bernatchez; Anick Langlois; Julyanne Brassard; Nicolas Flamand; David Marsolais; Marie-Renée Blanchet
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

4.  Management of hypersensivity pneumonitis.

Authors:  Ioana O Agache; Liliana Rogozea
Journal:  Clin Transl Allergy       Date:  2013-02-04       Impact factor: 5.871

5.  Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis.

Authors:  Masahiro Yamashita; Takashi Mouri; Miyuki Niisato; Hiroo Nitanai; Hitoshi Kobayashi; Masahito Ogasawara; Ryujin Endo; Kazuki Konishi; Tamotsu Sugai; Takashi Sawai; Kohei Yamauchi
Journal:  BMJ Open Respir Res       Date:  2015-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.